GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AgeX Therapeutics Inc (AMEX:AGE) » Definitions » ROA %

AgeX Therapeutics (AgeX Therapeutics) ROA % : -114.37% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is AgeX Therapeutics ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. AgeX Therapeutics's annualized Net Income for the quarter that ended in Dec. 2023 was $-13.82 Mil. AgeX Therapeutics's average Total Assets over the quarter that ended in Dec. 2023 was $12.09 Mil. Therefore, AgeX Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -114.37%.

The historical rank and industry rank for AgeX Therapeutics's ROA % or its related term are showing as below:

AGE' s ROA % Range Over the Past 10 Years
Min: -327.19   Med: -191.17   Max: -68.32
Current: -141.73

During the past 7 years, AgeX Therapeutics's highest ROA % was -68.32%. The lowest was -327.19%. And the median was -191.17%.

AGE's ROA % is ranked worse than
89.04% of 1551 companies
in the Biotechnology industry
Industry Median: -34.84 vs AGE: -141.73

AgeX Therapeutics ROA % Historical Data

The historical data trend for AgeX Therapeutics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AgeX Therapeutics ROA % Chart

AgeX Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial -134.20 -191.17 -245.09 -327.19 -194.70

AgeX Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -411.96 -166.22 -86.07 -176.45 -114.37

Competitive Comparison of AgeX Therapeutics's ROA %

For the Biotechnology subindustry, AgeX Therapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AgeX Therapeutics's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AgeX Therapeutics's ROA % distribution charts can be found below:

* The bar in red indicates where AgeX Therapeutics's ROA % falls into.



AgeX Therapeutics ROA % Calculation

AgeX Therapeutics's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-14.803/( (3.241+11.965)/ 2 )
=-14.803/7.603
=-194.70 %

AgeX Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-13.824/( (12.21+11.965)/ 2 )
=-13.824/12.0875
=-114.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


AgeX Therapeutics  (AMEX:AGE) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-13.824/12.0875
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-13.824 / 0.308)*(0.308 / 12.0875)
=Net Margin %*Asset Turnover
=-4488.31 %*0.0255
=-114.37 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


AgeX Therapeutics ROA % Related Terms

Thank you for viewing the detailed overview of AgeX Therapeutics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


AgeX Therapeutics (AgeX Therapeutics) Business Description

Traded in Other Exchanges
Address
1101 Marina Village Parkway, Suite 201, Alameda, CA, USA, 94501
AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develops medicines designed to address some of the unsolved problems in aging. Its PureStem-derived cell-based therapeutic candidates in development are AGEX-VASC1, AGEX-BAT1 and AGEX-iTR1547.
Executives
Jean-christophe Renondin director 505 PARK AVENUE 14TH FLOOR, NEW YORK NY 10022
Juvenescence Us Corp. director, 10 percent owner 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Joanne M. Hackett director C/O AGEX THERAPEUTICS, INC.,, 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94708
Park Andrea Eun Jae officer: Chief Financial Officer C/O AGEX THERAPEUTICS, INC., 965 ATLANTIC AVE., SUITE 101, ALAMEDA CA 94501
Michael H May director 965 ATLANTIC AVENUE, SUITE 101, ALAMEDA CA 94501
Michael D West director, officer: Chief Executive Officer AGEX THERAPEUTICS, INC., 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94501
Michael H. Mulroy director 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Russell Skibsted officer: Chief Financial Officer 15 TRANQUILITY PLACE, LADERA RANCH CA 92694
Judith Segall officer: Corporate Secretary 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Hal Sternberg officer: Vice President-Research 935 PARDEE STREET, BERKELEY CA 94710
Annalisa Jenkins director C/O ARDELYX, INC., 34715 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
John F Mauldin director 3204 BEVERLY DRIVE, DALLAS TX 75205
Gregory Bailey director 4 A CHESHAM STREET, LONDON X0 SW1X8DT
Juvenescence Ltd 10 percent owner 1ST FLOOR, VIKING HOUSE, ST PAULS SQUARE, RAMSEY Y8 IM8 1GB
Nafees Naseer Malik officer: Chief Operating Officer C/O AGEX THERAPEUTICS, INC., 1010 ATLANTIC AVE, STE 102, ALAMEDA CA 94501